EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
about
Functions and mechanisms of long noncoding RNAs in lung cancerCo-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysisDevelopment of New Molecular EZH2 on Lung Cancer Invasion and MetastasisDiverse involvement of EZH2 in cancer epigeneticsMolecular pathways and therapeutic targets in lung cancerEzh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.Regulation and Role of EZH2 in CancerPrognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancerIn vivo molecular mapping of the tumor microenvironment in an azoxymethane-treated mouse model of colon carcinogenesis.PCAF-primed EZH2 acetylation regulates its stability and promotes lung adenocarcinoma progression.Enhancer of zeste homolog 2 as an independent prognostic marker for cancer: a meta-analysisAn Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers.Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells.EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transitionPrognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis.Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene MutationsSquamous Cell Cancers: A Unified Perspective on Biology and GeneticsIL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a reviewImmunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?Context-dependent actions of Polycomb repressors in cancer.Morphoproteomics, E6/E7 in-situ hybridization, and biomedical analytics define the etiopathogenesis of HPV-associated oropharyngeal carcinoma and provide targeted therapeutic options.Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer.JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells.Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters.Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.IncRNA H19 promotes tongue squamous cell carcinoma progression through β-catenin/GSK3β/EMT signaling via association with EZH2.MUC1-C activates EZH2 expression and function in human cancer cells.Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer.Highlight report: Limits of prognostication of non-small cell lung cancer.Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.miR-21 modulates the effect of EZH2 on the biological behavior of human lung cancer stem cells in vitro.
P2860
Q26738672-B455A676-7FB8-46EC-8BDA-40D7790CB1FAQ27345462-3998FFC3-8D8E-4E38-87A3-C170A75AD0BFQ27853296-69A5E7C4-4506-467F-A254-8F211F476292Q28072419-67E2C478-0774-460E-B6A7-E56A25026234Q28084911-1588ADB1-5718-4F43-88D5-3344CC8ED79DQ33688872-7672403B-A432-4004-920D-5C68C4EC9E3CQ33717790-C00EDABF-554A-41A0-9C90-40FE54628144Q33804215-ECB35E10-7AE9-41A3-81A5-F6B25A365DC1Q34043370-E613A213-E02B-42CA-BA7E-EF8686DD7D9DQ34226978-DC89CB5A-2D6A-4AA8-B082-286770E5BD6EQ35007556-1DED4C55-370D-4274-AB7A-02751E59F662Q35476750-8EDDE3AC-1C35-4148-8F01-CF85CA0D4DF4Q35606640-F1E30D89-D3E7-4501-AC10-66633E524CEDQ35825840-AB5343D9-45EF-45A8-8E45-029778D3AF6FQ35942323-FAFDD19D-0C82-4D74-BBCE-07082BEC3450Q36053940-7288A490-EFC6-4860-95CA-8130BAFE613EQ36179615-F864167A-E2A5-4992-A0BE-712A3D4B749FQ36453727-9907A5B8-6979-4F61-BD59-BEA2EA165F79Q36535735-544E567F-01A0-4F91-8392-D2945769BABCQ36909843-0F997E78-5CC0-44B3-A392-D88DEB9BD4FCQ36963605-EE9FF224-1C9C-43A8-B62C-45744C04A8EAQ37098331-1A4D54F2-AEC2-4E1B-BA8F-6F3390996955Q37437481-E021C891-A341-4BB8-B731-90E7A341A41DQ37636628-9F11A68C-5135-42C0-9B1F-40AD9DF9C6E9Q38253055-FDD03030-9C41-4D8E-BFF8-6B6B1C7DEC21Q38323055-AA127780-4747-469A-BA91-DFBBA6E275F9Q38518851-F40672E6-2C99-4A6C-91D2-53D66FEEF1B9Q38619611-68425E3C-DC5D-407F-A541-ACCDC9B52534Q38696030-C4BA2696-00D8-4E74-9D63-C6913E8C41DFQ38788734-0D6AF7A8-1370-4721-BD34-C1A018F575A3Q38915283-15190C6A-2005-40CE-8308-F1B41DF46FCCQ38993869-5E603D00-8411-48E7-A847-7C3F3C7A7B42Q39457118-F68EC994-206B-40E9-8BE2-A2D73FD46184Q41009749-D7D99CE7-160A-47F9-AA82-9DE8124AA9A6Q41126655-5474CC36-0ECB-4822-A734-62F74D9A1ABDQ41286875-50C3E655-3301-44DE-8DC4-01CB4E907128Q41317361-6D3DCB0B-52C0-4448-9F5F-3A79A981C0CDQ42343331-ABC541FA-200B-4C5B-B8FA-05F8326CE398Q45907759-F2AA1CA8-A5FE-41C0-91EF-2576B38D3805Q47093759-2F9309DA-6FC6-40D2-B5DF-496DB399F808
P2860
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EZH2 protein expression associ ...... non-small cell lung carcinoma.
@en
EZH2 protein expression associ ...... non-small cell lung carcinoma.
@nl
type
label
EZH2 protein expression associ ...... non-small cell lung carcinoma.
@en
EZH2 protein expression associ ...... non-small cell lung carcinoma.
@nl
prefLabel
EZH2 protein expression associ ...... non-small cell lung carcinoma.
@en
EZH2 protein expression associ ...... non-small cell lung carcinoma.
@nl
P2093
P2860
P1476
EZH2 protein expression associ ...... non-small cell lung carcinoma.
@en
P2093
Carmen Behrens
Cesar A Moran
David J Stewart
Erick Riquelme
George R Simon
Heather Lin
Hector Galindo
Humam Kadara
J Jack Lee
Luisa M Solis
P2860
P304
P356
10.1158/1078-0432.CCR-12-3946
P407
P577
2013-10-04T00:00:00Z